Search Result

Results for "

multiple kinase inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (16) Aryl Hydrocarbon Receptor (1) Aurora Kinase (3) Autophagy (5) Bcr-Abl (2) Btk (1) c-Fms (1) c-Kit (5) c-Met/HGFR (5) Casein Kinase (1) CDK (3) Checkpoint Kinase (Chk) (1) EGFR (5) Endogenous Metabolite (3) FLT3 (5) G Protein-coupled Receptor Kinase (GRK) (2) GSK-3 (2) HDAC (1) IKK (1) JAK (3) MAP3K (2) Necroptosis (1) PDGFR (2) Phosphatase (3) Phosphodiesterase (PDE) (2) Pim (1) Polo-like Kinase (PLK) (6) RIP kinase (1) STAT (1) Syk (1) TAM Receptor (3) VEGFR (7)
By Research Areas:	Cancer (36) Inflammation/Immunology (4) Metabolic Disease (1) Neurological Disease (5)

By Targets:

Apoptosis (16)

Aryl Hydrocarbon Receptor (1)

Aurora Kinase (3)

Autophagy (5)

Bcr-Abl (2)

Btk (1)

c-Fms (1)

c-Kit (5)

c-Met/HGFR (5)

Casein Kinase (1)

CDK (3)

Checkpoint Kinase (Chk) (1)

EGFR (5)

Endogenous Metabolite (3)

FLT3 (5)

G Protein-coupled Receptor Kinase (GRK) (2)

GSK-3 (2)

HDAC (1)

IKK (1)

JAK (3)

MAP3K (2)

Necroptosis (1)

PDGFR (2)

Phosphatase (3)

Phosphodiesterase (PDE) (2)

Pim (1)

Polo-like Kinase (PLK) (6)

RIP kinase (1)

STAT (1)

Syk (1)

TAM Receptor (3)

VEGFR (7)

By Research Areas:

Cancer (36)

Inflammation/Immunology (4)

Metabolic Disease (1)

Neurological Disease (5)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-142817

GRK6-IN-2	G Protein-coupled Receptor Kinase (GRK)	Cancer
GRK6-IN-2 (compound 10a) is a potent inhibitor of G protein-coupled receptor kinase 6 (GRK6) with an IC₅₀ of 120 nM. GRK6 is a critical kinase required for the survival of multiple myeloma (MM) cells. GRK6-IN-2 has the potential for the research of multiple myeloma .

HY-142812

GRK6-IN-1	G Protein-coupled Receptor Kinase (GRK)	Cancer
GRK6-IN-1 (compound 18) is a potent inhibitor of G protein-coupled receptor kinase 6 (GRK6) with an IC₅₀ of 120 nM. GRK6 is a critical kinase required for the survival of multiple myeloma (MM) cells. GRK6-IN-1 has the potential for the research of multiple myeloma .

HY-149636

Multi-target kinase inhibitor 2	EGFR CDK VEGFR	Cancer
Multi-target kinase inhibitor 2 (compound 5K) is a **multi-targeted kinase** inhibitor, and exhibits activity against EGFR, Her2, VEGFR2, and CDK2 enzymes, with IC₅₀ values ranging from 40 to 204 nM. Multi-target kinase inhibitor 2 shows cytotoxic effects were observed against HepG2, HeLa , MDA-MB-231 and MCF-7, with IC₅₀ of 41, 57, 51 and 59 μM. Multi-target kinase inhibitor 2 induces cell cycle arrest and apoptosis in HepG2 cells.

HY-149019

Antitumor agent-70	c-Kit Apoptosis	Cancer
Antitumor agent-70 (compound 8b) has anti-tumor activity and can induce cell apoptosis. Antitumor agent-70 inhibits multiple myeloma with an IC₅₀ value of 0.12 μM. Antitumor agent-70 is a potential multi-targeted kinase inhibitor especially for c-Kit .

HY-155804

RIP1 kinase inhibitor 8	Necroptosis RIP kinase	Inflammation/Immunology
RIP1 kinase inhibitor 8 (Compound 77) is a potent and highly selective dihydropyrazole (DHP) RIP1 kinase inhibitor with an IC₅₀ of 20 nM. RIP1 kinase inhibitor 8 prevents necrotic cell death. RIP1 kinase inhibitor 8 shows a favorable pharmacokinetic profile in multiple species .

HY-118266

BTdCPU 1 Publications Verification	Phosphatase Apoptosis	Cancer
BTdCPU is a potent heme regulated inhibitor kinase (HRI) activator that promotes eIF2α phosphorylation and induces apoptosis in Dexamethasone (HY-14648) (Dex)-resistant cancer cells. BTdCPU can be used in the study of cancers such as multiple myeloma and Dex-resistant multiple myeloma .

HY-14596

Genistein Maximum Cited Publications 39 Publications Verification NPI 031L	EGFR Autophagy Apoptosis Endogenous Metabolite	Cancer
Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.

HY-123697

VE-465

Aurora Kinase Cancer

VE-465 is an Aurora kinase inhibitor. VE-465 induces cancer cell apoptosis. VE-465 has anticancer effects in multiple tumor models .

VE-465	Aurora Kinase	Cancer
VE-465 is an Aurora kinase inhibitor. VE-465 induces cancer cell apoptosis. VE-465 has anticancer effects in multiple tumor models .

HY-141687

NSC 107512	CDK Apoptosis	Cancer
NSC 107512 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9). NSC 107512 is a class of sangivamycin-like molecules (SLM). NSC 107512 inhibits growth and induces apoptosis of multiple myeloma tumors .

HY-163471

PDGFRα/β/VEGFR-2-IN-1	PDGFR VEGFR	Cancer
PDGFRα/β/VEGFR-2-IN-1 (6f), a multiple PDGFRα/ß and VEGFR-2 tyrosine kinase inhibitor, particularly targets PDGFRα, PDGFRβ, and VEGFR-2 kinases with Nano molar concentrations .

HY-12470A

PF-4800567 hydrochloride	Casein Kinase	Cancer
PF-4800567 hydrochloride is a potent and selective inhibitor of?*casein kinase?1? (CK1?), with an?IC₅₀?of 32 nM, which is greater than 20-fold selectivity over CK1δ (IC50, 711 nM). PF-4800567 hydrochloride is useful in probing unique roles between these two kinases* in multiple signaling pathways .

HY-15160

TAK-960 2 Publications Verification	Polo-like Kinase (PLK)	Cancer
TAK-960 is an orally available, selective inhibitor of *polo-like kinase* 1 (PLK1), with an IC₅₀** of 0.8 nM. TAK-960 also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .

HY-15160B

TAK-960 dihydrochloride 2 Publications Verification	Polo-like Kinase (PLK)	Cancer
TAK-960 dihydrochloride is an orally available, selective inhibitor of *polo-like kinase* 1 (PLK1), with an IC₅₀** of 0.8 nM. TAK-960 dihydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 dihydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .

HY-15160A

TAK-960 hydrochloride	Polo-like Kinase (PLK)	Cancer
TAK-960 hydrochloride is an orally available, selective inhibitor of *polo-like kinase* 1 (PLK1), with an IC₅₀** of 0.8 nM. TAK-960 hydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 hydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .

HY-148810

Zongertinib BI 1810631	c-Met/HGFR	Cancer
Zongertinib (BI 1810631) is a potent and selective HER2 and EGFR tyrosine kinase inhibitor with IC₅₀ values of 13 nM and 579 nM, respectively. Zongertinib has antitumor activity and can be used in the study of multiple solid tumors .

HY-15160C

TAK-960 monohydrochloride	Polo-like Kinase (PLK)	Cancer
TAK-960 monohydrochloride is an orally available, selective inhibitor of *polo-like kinase* 1 (PLK1), with an IC₅₀** of 0.8 nM. TAK-960 monohydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 monohydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .

HY-12044

Cabozantinib S-malate 35+ Cited Publications XL184 S-malate; BMS-907351 S-malate	VEGFR Apoptosis	Cancer
Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-14596S

Genistein-d4 NPI 031L-d₄	EGFR Autophagy Apoptosis Endogenous Metabolite	Cancer
Genistein-d₄ is the deuterium labeled Genistein. Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis[1][2].

HY-14596R

Genistein (Standard) Maximum Cited Publications 39 Publications Verification NPI 031L (Standard)	EGFR Autophagy Apoptosis Endogenous Metabolite	Cancer
Genistein (Standard) is the analytical standard of Genistein. This product is intended for research and analytical applications. Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.

HY-163267

ZNL0325	Others	Others
ZNL0325 is a covalent probe based on pyrazolopyrimidine. ZNL0325 features an acrylamide side chain at the C3 position, which is capable of forming covalent bonds with multiple kinases that possess a cysteine at the αD-1 position, including BTK, EGFR, BLK, and JAK3. ZNL0325 can be used in the research of creating structurally distinct covalent kinase inhibitors .

HY-13016S1

Cabozantinib-d4 XL184-d₄; BMS-907351-d₄	VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis	Cancer
Cabozantinib-d₄ is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-138696

Zanzalintinib 1 Publications Verification XL092	TAM Receptor c-Met/HGFR VEGFR	Cancer
Zanzalintinib (XL092) is an orally active, ATP-competitive inhibitor of multiple receptor tyrosine kinases (RTKs) including MET, VEGFR2, AXL and MER, with IC₅₀s in cell-based assays of 15 nM, 1.6 nM, 3.4 nM, 7.2 nM respectively. Zanzalintinib exhibits anti-tumor activity. Zanzalintinib has the potential for kinase-dependent diseases and conditions research .

HY-16976

GDC-0339 2 Publications Verification	Pim	Cancer
GDC-0339 is a potent, orally bioavailable and well tolerated pan-Pim kinase inhibitor, with K_is of 0.03 nM, 0.1 nM and 0.02 nM for Pim1, Pim2 and Pim3, respectively. GDC-0339 is discovered as a potential treatment of multiple myeloma .

HY-P5904

Caveolin-1 (82-101) amide (human, mouse, rat) Caveolin-1 scaffolding domain peptide	c-Met/HGFR	Others
Caveolin-1 (82-101) amide (human, mouse, rat) (Caveolin-1 scaffolding domain peptide) is a peptide that reverses aging-associated deleterious changes in multiple organs. Caveolin-1 (82-101) amide (human, mouse, rat) inhibits tyrosine kinases .

HY-50514

AT9283 5 Publications Verification	JAK Aurora Kinase Bcr-Abl FLT3 Apoptosis Autophagy	Cancer
AT9283 is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, JAK2/3, Abl (T315I) and Flt3 (IC₅₀s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo .

HY-13016S

Cabozantinib-d6 XL184-d₆; BMS-907351-d₆	VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis	Cancer
Cabozantinib-d₆ is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively[1][2][3].

HY-147864

c-Fms-IN-12	c-Fms c-Kit Apoptosis	Cancer
c-Fms-IN-12 (Compound 4g) is an FMS kinase inhibitor. c-Fms-IN-12 can also inhibits c-KIT. c-Fms-IN-12 is a potential broad-spectrum anticancer agent against multiple cancer types. c-Fms-IN-12 induces A549 cell apoptosis .

HY-10058

AT9283 lactic acid	JAK Aurora Kinase Bcr-Abl FLT3 Apoptosis Autophagy	Cancer
AT9283 lactic acid is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, JAK2/3, Abl (T315I) and Flt3 (IC₅₀s ranging from 1 to 30 nM). AT9283 lactic acid inhibits growth and survival of multiple solid tumors in vitro and in vivo .

HY-12137

Volasertib 15+ Cited Publications BI 6727	Polo-like Kinase (PLK) Apoptosis	Cancer
Volasertib (BI 6727) is an orally active, highly potent and ATP-competitive *Polo-like kinase* 1 (PLK1)** inhibitor with an IC₅₀ of 0.87 nM. Volasertib inhibits PLK2 and PLK3 with IC₅₀s of 5 and 56 nM, respectively. Volasertib induces mitotic arrest and apoptosis. Volasertib, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models .

HY-12137A

Volasertib trihydrochloride BI 6727 trihydrochloride	Polo-like Kinase (PLK) Apoptosis	Cancer
Volasertib (BI 6727) trihydrochloride is an orally active, highly potent and ATP-competitive *Polo-like kinase* 1 (PLK1)** inhibitor with an IC₅₀ of 0.87 nM. Volasertib trihydrochloride inhibits PLK2 and PLK3 with IC₅₀s of 5 and 56 nM, respectively. Volasertib trihydrochloride induces mitotic arrest and apoptosis. Volasertib trihydrochloride, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models .

HY-157871

TAK1-IN-5	MAP3K	Cancer
TAK1-IN-5 (Compound 26) is an inhibitor of the transforming growth factor-β activated kinase (TAK1) with an IC₅₀ value of 55 nM. TAK1-IN-5 can inhibit the growth of MPC-11 and H929 cells with a GI₅₀ lower than 30 nM. TAK1-IN-5 can be used in the study of multiple myeloma .

HY-16462

CDK9-IN-2 5 Publications Verification	CDK	Cancer
CDK9-IN-2 is a special cyclin-dependent kinase 9 (CDK9) inhibitor, extracted from patent WO/2012131594A1, compound CDKI(8), has an IC₅₀ of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively.

HY-109192

Tolebrutinib 2 Publications Verification SAR442168; PRN2246	Btk	Neurological Disease
Tolebrutinib (SAR442168) is a potent, selective, orally active and brain-penetrant inhibitor of *Bruton tyrosine kinase* (BTK), with IC₅₀*s of 0.4 and 0.7 nM in Ramos B cells and in HMC microglia cells, respectively. Tolebrutinib exhibits efficacy in central nervous system immunity. Tolebrutinib can be used for the research of multiple* sclerosis (MS) .

HY-112306

Ripretinib DCC-2618	c-Kit PDGFR FLT3 VEGFR Apoptosis	Cancer
Ripretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFRA switch-control inhibitor. Ripretinib (DCC-2618) targets and binds to both wild-type and mutant forms of KIT and PDGFRA specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. Ripretinib (DCC-2618) also inhibits multiple other kinase targets, such as FLT3 and KDR (or VEGFR-2) . DCC-2618 exerts antineoplastic effect and induces apoptosis .

HY-114331

DLK-IN-1	MAP3K	Neurological Disease
DLK-IN-1 is a selective, orally active inhibitor of dual leucine zipper kinase (DLK, MAP3K12), with a K_i of 3 nM. DLK-IN-1 retains excellent CNS penetration and is well tolerated following multiple days of dosing at concentrations that exceed those required for DLK inhibition in the brain. DLK-IN-1 has activity in a model of Alzheimer’s Disease.

HY-153077

PFKFB3-IN-2	Phosphatase	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
PFKFB3-IN-2 is a 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) inhibitor. PFKFB3-IN-2 has potential applications in cancer, neurodegenerative diseases, autoimmune diseases, inflammatory diseases, multiple sclerosis, metabolic diseases, angiogenesis inhibition and other diseases .

HY-149718

Antitumor agent-123	JAK HDAC	Cancer
Antitumor agent-123 (Copmound 4d) effectively inhibits multiple kinase targets with anti-cancer effects, including JAK2, JAK3, HDAC1 and HDAC6, with IC₅₀ values of 34.6 and 2.6 μM for JAK2 and JAK3, respectively. Antitumor agent-123 exhibits moderate activity in solid tumor models .

HY-107592

ACHP	IKK STAT Apoptosis	Inflammation/Immunology Cancer
ACHP (compound 4j) is a selective and orally active IκB kinase inhibitor with IC₅₀ values of 8.5 nM and 250 nM for IKKβ and IKKα, respectively. ACHP can effectively inhibit the STAT3 signaling pathway and induce cancer cell cycle arrest and apoptosis. ACHP shows anti-inflammatory activity in a mouse ear edema model. ACHP can be used in anti-inflammatory and anti-cancer (such as multiple myeloma and leukemia) studies .

HY-123981

5MPN	Phosphatase	Cancer
5MPN is a first-in-class, potent, orally active and selective 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) inhibitor. 5MPN appears to be a competitive inhibitor of the F6P binding site (K_i=8.6 μM). 5MPN does not inhibit PFK-1 or PFKFB3. 5MPN targets the sugar metabolism of tumors and suppresses proliferation of multiple human cancer cell lines .

HY-109082

Cevidoplenib SKI-O-703	Syk	Inflammation/Immunology
Cevidoplenib (SKI-O-703) is an orally available inhibitor of *spleen tyrosine kinase* (Syk)*, with potential anti-inflammatory and immunomodulating activities. Cevidoplenib is also the mesylate form of SKI-O-592. Cevidoplenib and SKI-O-592 inhibits* BCR-mediated survival, proliferation, and differentiation of B cells. And SKI-O-592 potently inhibits multiple kinases with IC₅₀s of 6.2 nM (Syk), 1.859 μM (Jak2), 5.807 μM (Jak3), 0.412 μM (RET), 0.687 μM (KOR), 1.783 μM (FLT3), 16.96 μM (FGFR1), 5.662 μM (FGFR3), and 0.709 μM (Pyk2), respectively .

HY-128879A

VP3.15 dihydrobromide 1 Publications Verification	Phosphodiesterase (PDE) GSK-3	Neurological Disease
VP3.15 dihydrobromide is a potent, orally bioavailable and CNS-penetrant dual *phosphodiesterase (PDE)7- glycogen synthase kinase* (GSK)3** inhibitor, with IC₅₀s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively. VP3.15 dihydrobromide has neuroprotective and neuroreparative activities, thus as potential combined anti-inflammatory and pro-remyelinating therapies for multiple sclerosis (MS) .

HY-128879

VP3.15	Phosphodiesterase (PDE) GSK-3	Neurological Disease
VP3.15 is a potent, orally bioavailable and CNS-penetrant dual *phosphodiesterase (PDE)7- glycogen synthase kinase* (GSK)3** inhibitor, with IC₅₀s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively. VP3.15 has neuroprotective and neuroreparative activities, thus as potential combined anti-inflammatory and pro-remyelinating therapies for multiple sclerosis (MS) .

HY-117102

ANI-7	Aryl Hydrocarbon Receptor Checkpoint Kinase (Chk)	Cancer
ANI-7 is an activator of aryl hydrocarbon receptor (AhR) pathway. ANI-7 inhibits the growth of multiple cancer cells, and potently and selectively inhibits the growth of MCF-7 breast cancer cells with a GI₅₀ of 0.56 μM. ANI-7 induces CYP1-metabolizing mono-oxygenases by activating AhR pathway, and also induces DNA damage, *checkpoint Kinase* 2 (Chk2)** activation, S-phase cell cycle arrest, and cell death in sensitive breast cancer cell lines .

HY-151154

EGFR/HER2/DHFR-IN-1	EGFR	Cancer
EGFR/HER2/DHFR-IN-1 is a potent anticancer agent with high selectivity against MCF-7 breast cancer cells. EGFR/HER2/DHFR-IN-1 is a multiple inhibitor of EGFR/HER2 kinase and DHFR, with IC₅₀s of 0.153 μM, 0.108 μM, 0.291 μM, respectively. EGFR/HER2/DHFR-IN-1 arrests cell cycle at G1/S and induces cells apoptosis .

Highly Selective Inhibitors Library	4694 compounds
According to reports, most known kinase inhibitors exert their effects through competitive binding in highly conserved ATP pockets. Although genetic techniques such as RNA interference can inactivate specific genes, most kinases are multi domain proteins, each of which has an independent function. Highly selective inhibitors have higher efficiency than non-selective inhibitors, and the selectivity to the target is at least 100 times higher. Therefore, ensuring the validation of targets with the most selective inhibitors is crucial for a more thorough understanding of the pharmacology of the kinase field. The Highly Selective Inhibitors Library contains 4694 compounds, covering multiple targets and subtypes, such as GPCR protein family, Ion channel, multiple kinases, etc. The Highly Selective Inhibitors Library is an effective tool for screening different phenotypes

Cat. No.	Product Name	Category	Target	Chemical Structure